Blueprint Medicines Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BLUEPRINT MEDICINES, and what generic alternatives to BLUEPRINT MEDICINES drugs are available?
BLUEPRINT MEDICINES has two approved drugs.
There are seven US patents protecting BLUEPRINT MEDICINES drugs.
There are ninety-seven patent family members on BLUEPRINT MEDICINES drugs in forty countries and sixteen supplementary protection certificates in fourteen countries.
Summary for Blueprint Medicines
International Patents: | 97 |
US Patents: | 7 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Blueprint Medicines
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-005 | Jun 16, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-002 | Jan 9, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Blueprint Medicines | AYVAKIT | avapritinib | TABLET;ORAL | 212608-001 | Jan 9, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Blueprint Medicines Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2683127 | ⤷ Try a Trial |
Israel | 302209 | ⤷ Try a Trial |
Mexico | 2016004927 | ⤷ Try a Trial |
Portugal | 3409674 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Blueprint Medicines Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3057969 | 21C1013 | France | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/20/1473 20200925; FIRST REGISTRATION: - EU/1/20/1473 20200925 |
3057969 | SPC/GB21/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK PLGB52115/0001-0003 20200925; UK EU/1/20/1473(NI) 20200925 |
3057969 | C03057969/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68294 06.07.2023 |
3057969 | 10/2021 | Austria | ⤷ Try a Trial | PRODUCT NAME: AVAPRITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/20/1473 (MITTEILUNG) 20200925 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.